We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+25.81%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$241M
AUM Growth
+$50.3M
Cap. Flow
+$11.8M
Cap. Flow %
4.88%
Top 10 Hldgs %
9.37%
Holding
372
New
47
Increased
146
Reduced
160
Closed
17

Top Buys

Rank Stock Value
1
BEPC icon
Brookfield Renewable
BEPC
+$1.51M
2
WES icon
Western Midstream Partners
WES
+$926K
3
PSXP
PHILLIPS 66 PARTNERS LP
PSXP
+$707K
4
DK icon
Delek US
DK
+$681K
5
CVI icon
CVR Energy
CVI
+$669K

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$1.61M
2
AIMT
Aimmune Therapeutics
AIMT
+$1.13M
3
AIV
Aimco
AIV
+$1.1M
4
VIV icon
Telefônica Brasil
VIV
+$1.01M
5
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$988K

Sector Composition

Rank Sector Weight
1 Healthcare 29.53%
2 Real Estate 18.96%
3 Energy 16.61%
4 Materials 11.31%
5 Utilities 7.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRSN
201
DELISTED
Mersana Therapeutics
MRSN
$308K 0.13%
462
-157
-25% -$87.3K
NTLA icon
202
Intellia Therapeutics
NTLA
$1.52B
$308K 0.13%
5,662
-10,265
-64% -$373K
DTIL icon
203
Precision BioSciences
DTIL
$185M
$306K 0.13%
1,225
-148
-11% -$36.3K
TECX
204
Tectonic Therapeutic
TECX
$562M
$305K 0.13%
1,821
+650
+56% +$116K
CRNX icon
205
Crinetics Pharmaceuticals
CRNX
$8.88B
$303K 0.13%
21,487
+2,116
+11% +$29.5K
KRYS icon
206
Krystal Biotech
KRYS
$10.7B
$303K 0.13%
5,052
-1,794
-26% -$89.6K
ARWR icon
207
Arrowhead Research
ARWR
$12.1B
$302K 0.13%
3,938
-5,486
-58% -$351K
AXSM icon
208
Axsome Therapeutics
AXSM
$12.1B
$301K 0.12%
3,690
-579
-14% -$43.3K
CRSP icon
209
CRISPR Therapeutics
CRSP
$4.68B
$301K 0.12%
1,966
-3,189
-62% -$377K
FCT
210
First Trust Senior Floating Rate Income Fund II
FCT
$251M
$301K 0.12%
25,865
+489
+2% +$5.45K
DNLI icon
211
Denali Therapeutics
DNLI
$3.82B
$300K 0.12%
3,586
-8,878
-71% -$537K
TVRD
212
Tvardi Therapeutics
TVRD
$22.9M
$300K 0.12%
550
-19
-3% -$9.96K
ANNX icon
213
Annexon
ANNX
$814M
$299K 0.12%
+11,958
New +$308K
SRRK icon
214
Scholar Rock
SRRK
$5.92B
$299K 0.12%
+6,154
New +$223K
IGMS
215
DELISTED
IGM Biosciences
IGMS
$298K 0.12%
3,374
-1,559
-32% -$110K
ZNTL icon
216
Zentalis Pharmaceuticals
ZNTL
$329M
$297K 0.12%
+5,711
New +$258K
DCF
217
DELISTED
BNY Mellon Alcentra Global Credit Income 2024 Target Term Fund, Inc.
DCF
$297K 0.12%
35,039
+681
+2% +$5.52K
ALEC icon
218
Alector
ALEC
$169M
$296K 0.12%
19,563
+9,032
+86% +$112K
UROV
219
DELISTED
Urovant Sciences Ltd.
UROV
$296K 0.12%
+18,324
New +$227K
STRO icon
220
Sutro Biopharma
STRO
$393M
$295K 0.12%
+1,358
New +$225K
MORF
221
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$295K 0.12%
+8,778
New +$259K
CALA
222
DELISTED
Calithera Biosciences, Inc
CALA
$295K 0.12%
3,004
-12
-0.4% -$1.05K
BTAI icon
223
BioXcel Therapeutics
BTAI
$26.1M
$294K 0.12%
398
-7
-2% -$5.45K
MCI
224
Barings Corporate Investors
MCI
$343M
$294K 0.12%
22,320
-1,391
-6% -$17.7K
ISEE
225
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$294K 0.12%
+42,509
New +$272K
7 8
9
10 11

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
RC
Roubaix Capital Denver, Colorado $214M AUM 32.43% 1-Year Est. Return

Virtus ETF Advisers's Q4 2020 Portfolio in Review

As of Q4 2020, Virtus ETF Advisers held 372 positions worth $241M, up 26% from $191M the previous quarter. Its ten largest holdings account for 9.4% of the portfolio.

Virtus ETF Advisers deployed $11.8M of net new capital in Q4 2020, opening 47 new positions and adding to 146 existing holdings. Its largest new stake was Harmony Biosciences: 14,899 shares worth $539K.

By sector, the portfolio is most concentrated in Healthcare at 30% of assets, down from 32% a quarter earlier, followed by Real Estate and Energy.

On the sell side, the largest reduction was Amicus Therapeutics, an estimated $572K trimmed.

  • Virtus ETF Advisers's largest Q4 2020 buy was Harmony Biosciences: 14,899 shares worth $539K.
  • Virtus ETF Advisers added most to Brookfield Renewable in Q4 2020, an estimated $1.51M increase.
  • Virtus ETF Advisers's biggest Q4 2020 reduction was Amicus Therapeutics, cutting an estimated $572K.
  • Virtus ETF Advisers fully exited Immunomedics Inc in Q4 2020, selling an estimated $1.61M.
  • Virtus ETF Advisers's ten largest holdings make up 9.4% of its $241M portfolio in Q4 2020.
  • Virtus ETF Advisers opened 47 new positions and closed 17 in Q4 2020.
  • Virtus ETF Advisers's portfolio value rose 26% quarter-over-quarter to $241M.

Based on Virtus ETF Advisers's 13F filing for Q4 2020, filed 12 Feb 2021.